Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005021 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00005021: Completed Phase 1 study, sponsored by Fox Chase Cancer Center.
NCT00005021 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005021, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of topotecan, paclitaxel, and carboplatin with or without filgrastim in treating patients who have advanced solid tumor or lymphoma that has not responded to standard therapy.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- BIOLOGICAL filgrastim
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 1996-07 |
| Est. Completion | 2003-05 |
| Phase | Phase 1 |
What the finished NCT00005021 record still lists
NCT00005021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT00005021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005021 about?
NCT00005021 is a clinical study titled "Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining biological therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study t...
What is the current status of trial NCT00005021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 1996-07. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00005021?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), filgrastim (BIOLOGICAL), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00005021?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00005021's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia